Houston-based Complete Intelligence was just recognized by Capital Factory as the "Newcomer of the Year." Photo via completeintel.com

The business applications of artificial intelligence are boundless. Tony Nash realized AI's potential in an underserved niche.

His startup, Complete Intelligence, uses AI to focus on decision support, which looks at the data and behavior of costs and prices within a global ecosystem in a global environment to help top-tier companies make better business decisions.

"The problem that were solving is companies don't predict their costs and revenues very well," says Nash, the CEO and founder of Complete Intelligence. "There are really high error rates in company costs and revenue forecasts and so what we've done is built a globally integrated artificial intelligence platform that can help people predict their costs and their revenues with a very low error rate."

Founded in 2015, Complete Intelligence is an AI platform that forecasts assets and allows evaluation of currencies, commodities, equity indices and economics. The Woodlands-based company also does advanced procurement and revenue for corporate clients.

"We've spent a couple years building this," says Nash. "We have a platform that is helping clients with planning, finance, procurement and sales and a host of other things. We are forecasting equity markets; we are forecasting commodity prices, currencies, economics and trades. We built a model of the global economy and transactions across the global economy, so it's a very large, very detailed artificial intelligence platform."

That platform, CI Futures, has streamlined comprehensive price forecasting and data analysis, allowing for sound, data-based decisions.

"Our products are pretty simple," says Nash. "We have our basic off the shelf forecast which is called CI Futures, which is currencies, commodities, equities and economics and trade. Its basic raw data forecasts. We distribute that raw data on our website and other data distribution websites. We also have a product called Cost Flow, which is our procurement forecasting engine, where we build a material level forecasting for clients.


completeintel.com

"Then we have a product that we'll launch next year called Revenue Flow, which is a sales forecasting tool that will use balance of both client data and publicly available data to forecast client sales by product, by geography and so on and so forth. So we really only do three things: revenues, costs and raw data forecasts."

Forecasting across industries

Complete Intelligence's Cost Flow and Revenue Flow products are specific to direct clients. They are working with clients in the food and beverage sector, the energy sector, the chemical sector, and the technology sector.

"Anybody that manufactures a tangible good, should use our product," says Nash. "Because we can take their historical data we can configure their bills of material and they can see the exact cost and exact revenue of those products by month over time."

CI is not a consulting firm, so they offer their clients an annual license, which allows them to receive updated forecasts every month to understand how markets will iterate over time.

"We're integrating with the client's enterprise data," says Nash. "Whether it's their ERP system or their procurement system or their CRM, we're integrating with client's enterprise data, and we're creating forecast outlooks that are perfectly contextually relevant for client buying decisions."

Called out by Capital Factory

As a business solution, CI has garnered widespread industry confidence and accolades, such as Capital Factory's coveted "Newcomer of the Year" award, which recognizes innovative companies from a pool of 110 startups in Texas.

"Honestly, I couldn't believe it because with a startup like ours, there's so much hard work that goes into it, there's so much time, there's so much persistence," says Nash.

"And the types of startups that Capital Factory attracts are very competitive startups, so for us to receive this award, it's given us a huge amount of credibility in the market and it's really encouraged the team inside the company to understand that what we're doing is being recognized, it's meaningful and we're really going places."

From consulting to billions of monthly calculations

Nash is no stranger to going places. Before setting up shop in his native Texas, he lived in Singapore for 15 years where he started his career in sourcing and procurement for American retail firms.

"I became very sensitive to costs, cost inflections and I got very involved in global sourcing and international trade and then I did a couple of corporate turnarounds and start ups and so with that you see costs as an issue with those types of firms," Nash says.

He then worked with the Economist running their global research business. There, he grew familiar with how clients and customers use data. At IHS Markit, a global information provider.

"When I was working with those firms, those firms helped companies with planning," says Nash. "The problem is that those firms have very large errors in their forecasts. It is not just the internal forecasts that have a 30 percent or higher error rate in their forecasts, even the industry forecasters typically have around a 20 percent error rates in their forecasts.

"Even the people who should actually know where prices are going are not very good forecasters. With Complete Intelligence, we wanted to use data and use artificial intelligence to machine learning to create a better way to identify where costs and revenues will go for companies."

Every month, CI runs billions of calculations. They test their error rates and record them for clients that request them. With 700 assets that they show publicly, CI their average error rate is 3.7 percent, which is dramatically lower than both corporate procurement professionals and industry experts.

"With us doing billions of calculations, it allows us to run simulations and scenarios that your average analyst just can't do and most companies haven't even thought of. We're able to run a comprehensive view of activities in the world to understand how things directly and indirectly affect a cost. In Houston, for example, that could be crude oil or natural gas or something like that."

Proving its value

Last year, the company tested its platform with a natural gas trader. After reviewing the data, CI revealed to the client that natural gas would fall by 40 percent over the next year.

"They looked at our forecast and said they couldn't work with us because it didn't make sense," says Nash. "A 40 percent fall didn't make sense, so they didn't subscribe to us. That was 2018. What has happened over the past 12 months? Natural gas prices had fallen by 49 percent. You would look at our forecasts and say, 'Wow, that's a dramatic drop over 12 months.' But reality was even more dramatic than that and there weren't analysts out there saying what our model was telling us."

That natural gas trading company never admitted its faux pas, but if they had listened to CI, they could have positioned themselves to negotiate their vendors down for their cost base, which helps the margin of their business.

"Nobody ever admits mistakes," says Nash. "But when you think about the numerous materials that require natural gas, especially things that are manufactured in Houston, it affects a lot of costs."

Houston roots — by way of Asia

The missed opportunity with the natural gas trader notwithstanding, Nash is happy that he brought Complete Intelligence to Houston.

"I went to Texas A&M and grew up in Texas, so I moved back to Texas knowing how good Americans are with planning, with math and with data. I like Houston because people make stuff in Houston," Nash says. "We just found Houston to be perfect after spending 15 years in Asia given the global centrality of Houston. The industry's here and there's a lot of diversity in Houston."

Nash's expectation was that he would be able to work with Western multinationals to improve their analytics and their artificial intelligence processes because he has learned that there is a lot of pressure in American financial markets and analysts communities to really know what is happening within companies.

"We want companies to be able to really tightly plan their costs so they can better improve their profitability," says Nash. "That's what I wanted to do when we moved to the U.S. and we're finding that there's a lot of interest from companies."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”

Houston business mogul Tilman Fertitta acquires Caesars in $17.6B deal

Money Moves

Houston billionaire Tilman Fertitta may currently be serving as America’s ambassador to Italy, but his company is as busy as ever. Fresh off its move to revive the Houston Comets WNBA franchise, his company, Fertitta Entertainment, has announced a $17.6 billion deal to acquire Caesars Entertainment, Inc.

Speculation about the deal has been circulating since at least March, according to various media reports. The deal combines Fertitta’s well-known Golden Nugget casino brand with all of the properties in the Caesars’ portfolio, including Las Vegas hotels Caesars Palace, Harrah's, Paris Las Vegas, Planet Hollywood, Horseshoe, The LINQ Hotel, Flamingo, and The Cromwell.

Overall, the combined company will include 60 domestic casino resorts and gaming facilities; online gaming including sports betting, iCasino, and Caesar’s online poker platform; retail sports betting at over 200 third-party locations through the William Hill brand; and over 550 Fertitta Entertainment outlets, including more than 450 Landry's full-service restaurants across America. The companies will combine their loyalty programs, Caesars Rewards, Golden Nugget's 24 Karat Select Club, and Landry's Select Club.

The terms will see Caesars’ shareholders receive $31 per share. Fertitta Entertainment will also acquire approximately $11.9 billion of Caesars' outstanding debt.

The transaction will be financed through a combination of equity contributed by Fertitta Entertainment, assumed Caesars' debt, and new committed debt financing arranged by a group consisting of 10 banks. It is subject to approval by Caesars’ shareholders and government regulators.

Fertitta Entertainment is the Houston-based company behind a diverse array of hospitality businesses, including The Golden Nugget, The Post Oak Hotel, River Oaks District, the Kemah Boardwalk, and Houston’s Downtown Aquarium.

It also operates a number of prominent restaurant brands, including Mastro's Restaurants, Del Frisco's Double Eagle Steakhouse, Morton's The Steakhouse, The Palm, McCormick & Schmick's, Landry's Seafood House, The Oceanaire Seafood Room, and Saltgrass Steak House.

---

This article first appeared on CultureMap.com.

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

  • A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
  • The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
  • Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
  • A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

  • $12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
  • $11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
  • $8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
  • $6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
  • $4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
  • $2.75 million to Rice, including $250,000 for a study of ovarian cancer.
  • $2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
  • $1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
  • $900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
  • $800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
  • $659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
  • $250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.